SP
IRWD icon

Stonebrook Private’s Ironwood Pharmaceuticals IRWD Stock Holding History

Stonebrook Private’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.4K Sell
10,926
-59
-0.5% -$242 0.01% 224
2025
Q4 		$37K Hold
10,985
– – 0.01% 209
2025
Q3 		$14.4K Buy
+10,985
New +$11.4K ﹤0.01% 208

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonebrook Private's IRWD Position: Q1 2026 in Review

Stonebrook Private reduced its Ironwood Pharmaceuticals (IRWD) stake by 0.54% in Q1 2026, selling an estimated $242 and leaving 10,926 shares worth $38.4K. The position accounts for 0.01% of the portfolio, ranked #224.

Stonebrook Private first reported a position in IRWD in Q3 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Stonebrook Private held 10,926 shares of Ironwood Pharmaceuticals worth $38.4K as of Q1 2026.
  • Stonebrook Private sold 59 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $242.
  • Ironwood Pharmaceuticals made up 0.01% of Stonebrook Private's portfolio in Q1 2026, its #224 holding.
  • Stonebrook Private first reported a position in Ironwood Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Stonebrook Private's 13F filing for Q1 2026, filed 11 May 2026.